Download Center >> Case Studies and App Notes

CASE STUDY: Biomarker Discovery in Human Prostate Cancer Patient Samples Using Combined MuDPIT and BIOiTRAQ Workflows

The discovery of protein biomarkers provides a solid basis for early stage disease prognosis and mechanisms for the prediction of patient responses to therapeutics. This information is also critical for the clinicians and scientists who are dedicated to unlocking the mysteries of disease pathways for targeting innovative therapeutic strategies. Toolsets which provide the ability to not only characterize, but to quantify new protein biomarkers are of great interest to today's researchers and clinicians. In addition, the ability to compare quantitative differences in identified biomarkers between patient groups or treatment regimens provides an additional level of value and insight.

Protea's LC-MS Services team has assisted multiple clients in identifying and quantifying protein biomarkers. Questions such as these are best answered with a multi-tiered, analytical approach. A critical first step is to obtain global proteomic "snapshot" of the proteins in a given sample using Multidimensional Protein Identification Technology (MuDPIT) combined with LC-MS/MS. Simultaneous identification and relative quantification of proteins can be delivered using a BIOiTRAQ approach as a second layer of analysis. This powerful combination of protein biomarker discovery with relative quantitative workflows significantly enhances experimental efficiency based on maximal protein discovery and sample multiplexing.

This case study highlights the utility of combining these two workflows for biomarker discovery and relative protein quantitation for samples of human plasma and urine. The overall goal was to investigate plasma and urine samples derived from normal patients as compared to those with early and late stage prostate cancer.

...innovations for bioanalytics